BioMS Medical receives 38 additional patents for multiple sclerosis drug MBP8298
Advertisement
BioMS Medical Corp, a developer in the treatment of multiple sclerosis (MS), announced that the University of Alberta has received thirty-eight additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta. In total, 88 patents have been granted to the University of Alberta for MBP8298 in 29 countries, including seven patents issued in the United States.